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Abstract
Prostate cancer is the most common non-cutaneous cancer and the second leading cause of cancer-related mortality among men in the USA.
Growing evidence suggests that oxidative stress is involved in the development and progression of prostate cancer. In this study, the
association between antioxidants from diet and supplements and biomarkers of oxidative stress in blood (n 278), urine (n 298) and prostate
tissue (n 55) were determined among men from the North Carolina-Louisiana Prostate Cancer Project. The association between antioxidant
intake and oxidative stress biomarkers in blood and urine was determined using linear regression, adjusting for age, race, prostate cancer
aggressiveness and smoking status. Greater antioxidant intake was found to be associated with lower urinary 8-isoprostane concentrations,
with a 10 % increase in antioxidant intake corresponding to an unadjusted 1·1 % decrease in urinary 8-isoprostane levels (95 % CI −1·7, −0·3 %;
P value< 0·01) and an adjusted 0·6 % decrease (95 % CI −1·4, 0·2 %; P value= 0·16). In benign prostate tissue, thioredoxin 1 was inversely
associated with antioxidant intake (P= 0·02). No significant associations were found for other blood or urinary biomarkers or for
malignant prostate tissue. These results indicate that antioxidant intake may be associated with less oxidative stress among men diagnosed
with prostate cancer.
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Prostate cancer is the most common non-cutaneous cancer and
the second leading cause of cancer-related mortality in men in
the USA, with an estimated 220 800 new cases and 27 540
deaths in 2015(1). The specific causes of prostate cancer have
not yet been determined, but several risk factors have been
identified for the disease – namely, family history, age and
race(2,3). However, the mechanisms by which these and other
risk factors, such as lifestyle, contribute to prostate cancer are
not clear, and there is likely a great degree of heterogeneity in
the causes of the disease.
At the cellular level, a growing body of evidence indicates
that oxidative stress is involved in prostate carcinogenesis(4).
Reactive oxygen species (ROS) can promote carcinogenesis by
causing oxidative damage to DNA and macromolecules within
cells, altering signal transduction pathways, and promoting a
malignant phenotype(4). Furthermore, antioxidant enzyme
genotype has been associated with cancer risk(5), and prostate
cancer risk may be modified by interactions between anti-
oxidant enzyme genotype and dietary antioxidants(6,7). Men
diagnosed with prostate cancer have been shown to have
greater oxidative stress, lower antioxidant enzyme activity(8)
and greater levels of urinary isoprostanes – a biomarker of
oxidative stress and lipid peroxidation(9,10). Furthermore,
in vitro experiments have implicated the production of ROS in
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the aggressiveness of prostate cancer cells(11). Thus, relatively
consistent evidence suggests an association between oxidative
stress and prostate cancer.
Oxidative stress is regulated in both benign and malignant
cells via several non-enzymatic and enzymatic antioxidant
mechanisms(4). Malignant cells have greater levels of ROS and
compensatory increases in antioxidant enzymes in order to
tolerate increased oxidative stress(12). However, the evidence
for a relationship between dietary antioxidants and prostate
cancer is inconsistent in humans(13), which is partly due to the
relatively small number of dietary antioxidants studied and
their diversity in structure and possible mechanisms of action.
Dietary antioxidants such as flavonoids have been shown to
reduce oxidative damage(14) and promote DNA repair(15) in
prostate cancer cells in vitro. Thus, dietary antioxidants could
have some effect on prostate cancer, possibly by affecting
oxidative stress.
The discrepant findings regarding prostate cancer and dietary
antioxidants prompted this study of dietary antioxidant intake
using a cumulative index of the antioxidant capacity of diet
and supplements(16). A cumulative measure of antioxidant
intake from diet and supplements may circumvent issues of
multiplicity in associations between individual dietary
antioxidants and disease risk. Such an estimate of dietary
antioxidant intake has been studied recently with regard to
prostate cancer incidence(17); however, little is known about the
relationship between dietary antioxidants and levels of
oxidative stress among prostate cancer patients. Therefore, the
objectives of this study were to measure the dietary antioxidant
intake and biomarkers of oxidative stress of men diagnosed
with incident prostate cancer and to determine whether
antioxidant intake is inversely related to oxidative stress.
Methods
The present study used data collected by the North Carolina-
Louisiana Prostate Cancer Project (PCaP), a population-based
study of incident prostate cancer(18). In brief, men between
40 and 79 years of age with a first diagnosis of histologically
confirmed adenocarcinoma of the prostate on or after 1 July
2004, were eligible to participate in the PCaP. Men had to be
able to complete the study interview in English and could not
live in an institution or nursing home, be cognitively impaired,
under the influence of alcohol, severely medicated or
apparently psychotic. Men must have self-identified as either
African-American or black or Caucasian or white when
responding to the question ‘What is your race?’ This project was
approved by the institutional review boards at the Department
of Defense Prostate Cancer Research Program, the University of
North Carolina and Louisiana State University. The institutional
review board at the University of Connecticut also approved
this study.
Dietary antioxidants
Dietary data were collected using a modified version of the
National Cancer Institute Diet History Questionnaire (DHQ)(19),
which assessed average daily dietary intake for 1 year before
diagnosis, and supplement data were collected via a ques-
tionnaire administered by a PCaP nurse. Data regarding flavonoid
and proanthocyanidin contents of foods were added to the DHQ
database using Nutrition Data System for Research, version 2011
(Nutrition Coordinating Center, University of Minnesota). The
2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS)
radical anion scavenging activity assay was used previously to
measure the vitamin C equivalent (VCE) antioxidant capacities of
individual antioxidants(20) and the values were applied to the
PCaP diet and supplement data. Antioxidant intake was
calculated from the VCE antioxidant capacity of forty-two dietary
antioxidants (carotenoids, vitamins C and E, flavonoids,
proanthocyanidins and isoflavones) and five antioxidants from
dietary supplements (vitamin C, α-tocopherol, β-carotene,
lycopene, and lutein and zeaxanthin).
Blood and urinary biomarkers of oxidative stress
Urine, erythrocyte, plasma and tissue samples were available
from 298, 271, 279 and fifty-nine men, respectively, and these
samples were collected from men who reported not having
undergone any treatment for their prostate cancer, as it was
thought that treatment might influence reporting of dietary
recall or oxidative stress. Blood and urine samples were
collected from PCaP research subjects at the time of interview,
centrifuged, aliquoted and stored at −80°C until analysis. The
activities of erythrocyte glutathione peroxidase, glutathione
S-transferase, glutathione reductase and superoxide dismutase,
as well as the concentrations of plasma malondialdehyde and
urinary 8-isoprostane and creatinine, were measured using
commercial kits (Cayman Chemical Company) according to the
manufacturer’s instructions. Plasma antioxidant capacity was
measured using the ABTS radical anion scavenging activity
assay. In brief, 2,2′-azobis(2-amidinopropane) HCl and ABTS
were dissolved in potassium phosphate buffer solution and
heated to 70°C for 30 min. The mixture was then cooled to
room temperature and diluted to reach an absorbance of
0·650± 0·020 at 734 nm. This solution was added to the plasma
samples, and the absorbance was measured at 734 nm after
10 min. Plasma antioxidant capacity was calculated in VCE
using a vitamin C standard curve.
Prostate tissue thioredoxin 1
Paraffin-embedded prostate tissue biopsy specimens were
selected from PCaP research subjects who were untreated at the
time of sample collection to provide an approximately equal
proportion of subjects by site, race and aggressiveness level to
yield a subsample of fifty-nine tissue sections (5-µm thickness)
for analysis. Sections were deparaffinised, rehydrated under an
alcohol gradient and antigen retrieved using Reveal Decloaker
(Biocare Medical) for 15 min at 110°C in a Decloaking Chamber
(Biocare Medical). Sections were blocked for endogenous
peroxidase activity using 3 % H2O2, rinsed with deionised,
distilled water for 10 min at room temperature, blocked with
normal goat serum for 1 h and incubated overnight at 4°C with
rabbit anti-thioredoxin 1 (1:1000; Cell Signaling). The next day,
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sections were incubated for 30 min at room temperature with
Rabbit SignalStain Boost IHC Reagent, the enzymatic activity
was revealed using diaminobenzidine (Sigma-Aldrich), counter-
stained with haematoxylin (Vector Laboratories) and mounted
using a permanent mounting medium. Images of the stained
sections were collected using a Leica DFC0425C camera (Leica)
mounted on a Leica DMRA2 microscope (Leica) equipped with
an automated stage. Prostate cancer Gleason’s scores of all the
biopsy sections were determined by a genitourinary pathologist
(G. A.). Levels of thioredoxin 1 (Trx1) in benign and malignant
tissue were visually scored by GA in a blinded manner. Slides
were scored from 0 to 3, with 0 indicating absence of staining
and 1 through 3 indicating greater intensity of staining.
A total of fifty-nine prostate biopsy specimens were randomly
selected for analyses. Some of the samples were excluded from
the analyses because sections that contained malignant tissue
were unavailable for four biopsies and sections containing
benign tissue were unavailable for three biopsies. The final
number of prostate biopsy specimens used for the analyses of
Trx1 were fifty-five malignant tissue and fifty-four benign tissue
samples.
Statistical analyses
All the statistical analyses were performed using SAS software,
version 9.3 (SAS Institute Inc.). Men were ranked into three
groups based on dietary antioxidant intake, and descriptive
statistics are reported for each group (Tables 1 and 2).
Antioxidant intake was adjusted for average energy intake using
the residual method(21). Linear regression was used to deter-
mine the association between antioxidant intake from diet and
supplements and biomarkers of oxidative stress, adjusting
for average energy intake, age, race, prostate cancer aggres-
siveness and smoking status. On the basis of residual plots,
antioxidant intake, plasma glutathione S-transferase activity,
erythrocyte glutathione reductase activity and urinary
8-isoprostane levels were log transformed to improve linearity.
As for all regression models antioxidant intake was log trans-
formed, the associations between intake of antioxidants
and biomarkers are reported as the predicted change in the
biomarker for a 10 % increase in dietary antioxidants. As
the range of antioxidant intake might differ between supple-
ment users and non-users and as supplement use might be
associated with other confounders, we tested for an interaction
between antioxidant intake and an indicator variable that
dichotomised supplement users and non-users. This interaction
allows for testing whether the association between antioxidant
intake and biomarkers differs between supplement users and
non-users. The association between Trx1 and categories of
antioxidant intake was determined using Fisher’s exact test. For
all the analyses, a P value of <0·05 was used to determine
statistical significance.
Results
The range in antioxidant intake (mg VCE/d) among men
in tertiles was 61–388 for tertile 1, 389–804 for tertile 2 and
829–4895 for tertile 3. Descriptive statistics for research subjects
are presented in Table 1. A greater proportion of white, older
and overweight and obese men, as well as men who reported
having a prostatic-specific antigen test, reported greater
antioxidant intake. The median levels of biomarkers by
dietary antioxidant intake are reported in Table 2. Plasma
malondialdehyde was the lowest and erythrocyte glutathione
peroxidase activity was the highest among men in the highest
tertile of antioxidant intake. Urinary 8-isoprostane level was
inversely associated with dietary antioxidant intake, with levels
of 8-isoprostane decreasing across tertiles.
In linear regression models of antioxidant intake predicting
biomarkers of oxidative stress, there was no statistically
significant interaction between supplement use and antioxidant
intake in both unadjusted and adjusted analyses, which
indicates that the association between antioxidant intake and
biomarkers did not significantly differ between users and
non-users of dietary supplements. There was little evidence of
an association between dietary antioxidant intake and
biomarkers from plasma or erythrocytes (Table 3). In
unadjusted analyses, urinary 8-isoprostane was significantly
associated with antioxidant intake, with a 10 % increase in
antioxidant intake corresponding to a 1·1 % decrease in urinary
8-isoprostane (95 % CI −1·9, −0·3 %; P value< 0·01). After
adjusting for age, race, aggressiveness and smoking status,
this association was no longer statistically significant; however,
the direction of the association was similar, with a 10 % increase
in antioxidant intake associated with a 0·6 % decrease in urinary
8-isoprostane (95 % CI −1·4, 0·2 %; P value= 0·16). After
adjustment, there was some evidence of a weak inverse
association between antioxidant intake and erythrocyte
glutathione S-transferase activity, with a 10 % increase in
antioxidant intake corresponding to a predicted decrease in
erythrocyte glutathione S-transferase activity of 0·5 (95 % CI
−1·0, 0·0 nmol/min per ml; P value= 0·05). There was no
evidence of an association between Trx1 in malignant
prostate tissue and dietary antioxidant intake (P value= 0·90)
(Table 4); however, there was evidence of an inverse
association between antioxidant intake and Trx1 in benign
prostate tissue (P value= 0·02).
Discussion
Men with prostate cancer have been found to have low blood
levels of dietary antioxidants(23), decreased activity of
endogenous antioxidant enzymes and increased levels of lipid
peroxidation(8,24). These findings could indicate either greater
oxidative stress, resulting in depletion of antioxidants, or lower
levels of antioxidants, resulting in increased oxidative
stress and lipid peroxidation. Furthermore, levels of anti-
oxidants in the blood may interact with genetic variants of
cyclo-oxygenase-2 and IL-8, which are involved in inflamma-
tion(25), and human oxoguanine glycosylase 1 and X-ray repair
cross-complementing group 1, which are involved in repairing
DNA damage(7,26). Thus, it is plausible that dietary antioxidants
may influence prostate cancer development and progression
with oxidative stress-mediated damage.
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The present study was unable to establish the direction of
cause and effect, due to its cross-sectional design. However, the
significant, inverse associations between dietary antioxidants
and levels of urinary 8-isoprostane suggest that the oxidative
stress of men with prostate cancer may in part depend on
diet. This may indicate that men with greater intake of dietary
antioxidants have greater inhibition of free radicals and subse-
quently less lipid peroxidation(27). It is also possible that the
inverse association observed may reflect some non-antioxidant
mechanisms of dietary components assumed to function as
Table 1. Socio-demographic and clinical characteristics by tertile (T) of antioxidant intake
(Numbers and percentages)
Antioxidant intake
T1 T2 T3
n % n % n %
Age (years)
<50 6 46·2 4 30·8 3 23·1
51–60 24 34·3 22 31·4 24 34·3
61–70 25 29·4 27 31·8 33 38·8
>70 11 20 24 43·6 20 36·4
Race
White 32 26·9 38 31·9 49 41·2
Black 34 32·7 39 37·5 31 29·8
BMI
Normal 16 36·4 16 36·4 12 27·3
Overweight 26 28 34 36·6 33 35·5
Obese 24 27·9 27 31·4 35 40·7
Smoking history
Non-smoker 16 21·6 27 36·5 31 41·9
Former smoker 35 31·8 35 31·8 40 36·4
Smoker 15 38·5 15 38·5 9 23·1
Aggressiveness*
Low 43 28·7 51 34 56 37·3
Intermediate 16 31·4 19 37·3 16 31·4
High 7 31·8 7 31·8 8 36·4
PSA test
Yes 44 25·6 57 33·1 71 41·3
No 22 43·1 20 39·2 9 17·6
Family history†
Yes 10 41·7 4 16·7 10 41·7
No 56 28·1 73 36·7 70 35·2
PSA, prostatic-specific antigen.
* High aggressive defined as Gleason’s sum ≥8 or PSA>20 ng/ml or Gleason’s sum= 7 and clinical stage T3–T4; low aggressive as Gleason’s
sum<7 and clinical stage T1–T2 and PSA<10 ng/ml; all other cases were defined as intermediate aggressive.
† Defined as having at least one relative diagnosed with prostate cancer before 60 years of age.
Table 2. Antioxidant biomarkers by tertile (T) of antioxidant intake
(Medians and interquartile ranges (IQR))
Antioxidant intake
T1 T2 T3
Median IQR Median IQR Median IQR
Plasma
TAC (mg VCE/l) 63·9 57·9, 70·0 63·8 53·0, 69·9 63·1 53·5, 68·8
MDA (µM) 207·7 170·9, 243·5 209·2 177·5, 238·7 197·7 170·2, 255·6
GST activity (nmol/min per ml) 14·4 13·0, 16·3 15·3 12·4, 17·5 15·9 13·9, 18·3
Erythrocytes
GST activity (nmol/min per ml) 46·1 33·4, 61·6 44·9 27·2, 66·6 43·3 25·8, 63·2
GPx activity (nmol/min per ml) 764·1 438·1, 985·7 745·0 483·9, 995·8 841·8 556·8, 1031·5
GR activity (nmol/min per ml) 207·8 151·8, 290·3 223·1 170·6, 285·3 224·1 157·9, 309·2
SOD activity (U/ml)* 76·3 69·8, 78·8 73·2 68·9, 78·8 74·7 69·4, 78·8
Urine
8-Isoprostane (ng/mmol creatinine) 140·0 103·1, 195·5 121·2 85·2, 193·5 116·2 82·5, 151·8
TAC, total antioxidant capacity; VCE, vitamin C equivalents; MDA, malondialdehyde; GST, glutathione S-transferase; GPx, glutathione peroxidase; GR, glutathione reductase; SOD,
superoxide dismutase.
* One unit of SOD is defined as the amount of enzyme needed to exhibit 50% dismutation of the superoxide radical.
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antioxidants in vivo. There was no observed difference in this
association among men with different levels of prostate cancer
aggressiveness (data not shown). This, combined with the
limitations inherent to a cross-sectional study, does not allow for
the determination of whether the association between diet
and oxidative stress observed among these men will reflect
meaningful clinical outcome measures, such as disease
progression and mortality.
There was little or no evidence of an association between
antioxidant intake and the activity of plasma or erythrocyte
antioxidant enzymes, and the association between dietary
antioxidants and erythrocyte glutathione S-transferase could be
due to chance. There are several explanations for this absence
of effect. Arsova-Sarafinovska et al.(8) found that erythrocyte
antioxidant enzyme activity was decreased in prostate cancer
patients compared with controls. As the present study included
only men diagnosed with prostate cancer, differences between
healthy men and those with prostate cancer may be greater than
differences among men with prostate cancer. Other studies
have demonstrated that polymorphisms in the genes of anti-
oxidant enzymes are related to prostate cancer(5,6); antioxidant
enzyme activity, as assessed in this study, may not be sensitive
enough to capture functional differences in antioxidant
enzymes that result from differences in amino acid sequences.
Furthermore, antioxidants in plasma or erythrocytes may not
reflect prostate tissue antioxidant activity. The null finding
regarding diet and malondialdehyde could reflect the method of
measurement. Malondialdehyde was measured using the thio-
barbituric acid reactive substances method, which may not be a
sensitive measure of lipid peroxidation and oxidative stress(28).
The primary strength of this study was the use of a prostatic
biomarker to assess prostate tissue redox status. Trx1 in benign
prostate tissue was found to be inversely associated with anti-
oxidant intake (Table 4). Trx1 is thought to be involved in
prostate carcinogenesis and may indicate redox imbalance in
prostate cancer(29). Thioredoxin reductase 1 (TrxR1) transfers
electrons from NADPH to Trx1, a process that occurs in most
living cells and is essential for the maintenance of cellular redox
Table 3. Association between oxidative stress biomarkers and dietary antioxidants from linear regression
(Changes and 95% confidence intervals)
Unadjusted Adjusted*
Biomarkers Change† 95% CI P Change† 95% CI P
Plasma
TAC (mg VCE/l) 0·0 −0·2, 0·2 0·81 −0·1 −0·3, 0·1 0·32
MDA (µM) 0·3 −0·6, 1·3 0·49 0·4 −0·6, 1·5 0·43
GST activity (nmol/min per ml) 0·3% −0·1, 0·8% 0·15 0·3% −0·2, 0·8% 0·18
Erythrocytes
GST activity (nmol/min per ml) −0·3 −0·8, 0·2 0·18 −0·5 −1·0, 0·0 0·05
GPx activity (nmol/min per ml) 4·9 −0·8, 10·6 0·09 3·7 −2·4, 9·9 0·24
GR activity (nmol/min per ml) 0·0% −0·8, 0·9% 0·94 −0·3% −1·2, 0·6% 0·55
SOD activity (U/ml) 0·0 −0·1, 0·2 0·63 0·0 −0·2, 0·2 0·73
Urine
8-Isoprostane (ng/mmol creatinine) −1·1% −1·9, −0·3% <0·01 −0·6% −1·4, 0·2% 0·16
TAC, total antioxidant capacity; VCE, vitamin C equivalents; MDA, malondialdehyde; GST, glutathione S-transferase; GPx, glutathione peroxidase; GR, glutathione reductase;
SOD, superoxide dismutase.
* Adjusted for age, race, aggressiveness and smoking status.
† Predicted change in biomarker for a 10% increase in dietary antioxidants.
Table 4. Thioredoxin 1 (Trx1) levels in malignant and benign tissue by tertile (T) of antioxidant intake*
(Numbers and percentages)
Antioxidant intake
T1 T2 T3
n % n % n % P†
Malignant Trx1
0 0 0·0 2 33·3 2 66·7 0·90
1 3 28·6 3 42·9 2 28·6
2 8 35·0 8 25·0 8 40·0
3 5 33·3 7 26·7 7 40·0
Benign Trx1
0 0 0·0 2 100·0 0 0·0 0·02
1 10 30·8 13 34·6 9 34·6
2 3 20·0 4 20·0 10 60·0
3 3 100·0 0 0·0 0 0·0
* Trx1 data from this sample has been published in Vance et al.(22).
† P value from Fisher’s exact test.
72 T. M. Vance et al.
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status(30). Both Trx1 and TrxR1 are increased in prostate cancer
cells(29,31), with a greater proportion of Trx1 in an oxidised state,
which may reflect redox imbalance and response to greater
levels of oxidative stress. Expression of TrxR1, the enzyme
responsible for maintaining Trx1 in a reduced form, has been
shown to be increased in castration-resistant prostate cancer(31).
Reduced Trx1 binds to apoptosis signal-regulating kinase 1 and
regulates cell death(32); thus, redox imbalance may promote
cancer cell survival. Taken together, greater levels of Trx1
correspond to more aggressive forms of prostate cancer. The
inverse association between antioxidant intake and Trx1
requires further research to determine whether this association
might affect disease severity or progression, particularly
given the relatively small number of tissue samples analysed in
this study. Relatively few studies have been conducted on the
thioredoxin system and prostate cancer; moreover, although
this system appears to play an important role in prostate
cancer, the extent to which this system affects prostate
cancer development and progression in humans remains
uncertain.
The present study has several limitations. The cross-sectional
design of the study prohibits establishing a cause–effect rela-
tionship between antioxidant intake and urinary 8-isoprostane
and prostate tissue Trx1. Dietary data were collected after
diagnosis and knowledge of disease may have biased responses
by research subjects, although this would likely have been
non-differential. The number of research subjects included in
the study was relatively low, particularly with regard prostate
tissue Trx1, which should be taken into consideration when
interpreting these results. The apparent inverse association
between antioxidant intake and Trx1 in benign prostate tissue is
tenuous based on available evidence. One interpretation of the
current data is that greater antioxidant intake reduces oxidative
stress, thereby inhibiting the activation of nuclear factor
(erythroid-derived 2)-like 2 and its promotion of Trx1
transcription(33). However, we did not measure the proportion
of oxidised and reduced Trx1 in prostate tissue, and this
additional data would have shed light on the observed
associations with Trx1 in the present study and oxidative
stress(29). Additional work is needed to confirm this association
and determine whether intake of antioxidants can influence
the oxidation state of Trx1 and oxidative stress in the prostate,
and whether these effects influence relevant clinical outcomes
such as prostate cancer mortality.
This study demonstrated that intake of antioxidants was
associated with less oxidative stress among men with incident
prostate cancer. The results of this study and others warrant
additional research in humans on the mechanisms underlying
the relationship between dietary antioxidants and prostate tis-
sue redox status and carcinogenesis, as well as determining
whether this relationship may influence disease severity, pro-
gression and recurrence.
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